# Agilent Technologies, Inc. (A)

> Source: Nexqual · https://nexqual.com/A · data as of 2026-10-22 20:03 UTC · cite as "Nexqual, Agilent Technologies, Inc. (A), nexqual.com/A" · informational, not investment advice.

**Price:** USD 173.89 (-2.17% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 177.75 · day 171.23–179 · 52w 108.35–179.1 · market cap $49.0B · NYQ

## Key facts
- Last four reported quarters (through Jul 31, 2026): revenue $7.37B, net income $1.44B (19.5% margin), free cash flow $1.27B (SEC filings).
- Valuation: P/E 34.0x (avg 28.7x at the last 3 fiscal year-ends), EV/EBITDA 26.8x, net debt $2.19B.
- 2 of 80 tracked superinvestors hold A (13F, Q2 2026): 0 new, 0 added, 1 reduced, 1 unchanged.
- Insider open-market sales, last ~7 months: 2 Form 4 filings, $313K; 2 not under a Rule 10b5-1 plan ($313K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Total return with dividends: 1Y +18.8% vs S&P 500 +14.9%; 5Y +14.1% vs S&P 500 +80.3%.
- Next earnings: 2026-11-25, EPS estimate USD 1.73, revenue estimate $1.99B.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $6.32B | $6.85B | $6.83B | $6.51B | $6.95B | $7.37B |
| Gross profit | $3.41B | $3.72B | $3.46B | $3.54B | $3.64B | — |
| Operating income | $1.35B | $1.62B | $1.35B | $1.49B | $1.48B | $1.64B |
| Net income | $1.21B | $1.25B | $1.24B | $1.29B | $1.30B | $1.44B |
| EPS (diluted) | $3.94 | $4.18 | $4.19 | $4.43 | $4.57 | — |
| Free cash flow | $1.30B | $1.02B | $1.47B | $1.37B | $1.15B | $1.27B |
| Gross margin | 53.9% | 54.4% | 50.7% | 54.3% | 52.4% | — |
| Operating margin | 21.3% | 23.6% | 19.8% | 22.9% | 21.3% | 22.2% |
| Net margin | 19.1% | 18.3% | 18.1% | 19.8% | 18.8% | 19.5% |
| Revenue growth | +18.4% | +8.4% | -0.2% | -4.7% | +6.7% | — |
| Cash + short-term investments | $1.48B | $1.05B | $1.59B | $1.33B | $1.79B | — |
| Total debt | $2.73B | $2.77B | $2.73B | $3.39B | $3.35B | — |
Fiscal years end Oct. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jul 31, 2026)
P/E 34.0x · P/S 6.7x · EV/EBITDA 26.8x · EV/Sales 7.0x · P/FCF 38.7x · P/B 6.7x · FCF yield 2.58% · Earnings yield 2.94% · Dividend yield (paid, TTM) 0.58% · Buyback yield (TTM) 0.78% · Net debt $2.19B · EV $51.2B
P/E at fiscal year-ends: Oct 2025 32.0x, Oct 2024 29.4x, Oct 2023 24.7x.

## Superinvestors (SEC 13F-HR, Q2 2026)
2 of 80 tracked investors hold A. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| William Von Mueffling | Cantillon Capital Management | 2.53% | $16.8M | Reduced -95.4% |
| Greenhaven Associates |  | 0.02% | $1.4M | Unchanged |

## Insider sales (SEC Form 4, open-market, last ~7 months)
0 of 2 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-09-04 | Dolsten Mikael | Director | 634 | $96K | 11.4% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-05-29 | Dolsten Mikael | Director | 1,600 | $217K | 22.4% | No | Too little history (no open-market trades in 2023 or 2024) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-13 | TD Cowen | Target raised | Buy | $180 → $196 |
| 2026-10-13 | Morgan Stanley | Target raised | Overweight | $175 → $190 |
| 2026-10-07 | Barclays | Target raised | Overweight | $175 → $195 |
| 2026-08-28 | Wells Fargo | Target raised | Overweight | $160 → $180 |
| 2026-08-27 | Stifel | Target raised | Buy | $170 → $180 |
| 2026-08-27 | B of A Securities | Target raised | Buy | $155 → $180 |
| 2026-08-27 | Citigroup | Target raised | Buy | $185 → $190 |
| 2026-08-27 | Goldman Sachs | Target raised | Buy | $155 → $175 |
| 2026-08-27 | JP Morgan | Target raised | Overweight | $180 → $190 |
| 2026-08-27 | TD Cowen | Target raised | Buy | $155 → $180 |
| 2026-08-27 | Bernstein | Target raised | Outperform | $155 → $180 |
| 2026-08-27 | RBC Capital | Target raised | Outperform | $155 → $185 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | +18.8% | +14.1% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +18.9% | +2.7% |
| Volatility (annualized) | 31.9% | 29.6% |
| Max drawdown | -29.8% (Nov 2025→Mar 2026) | -36.6% (Nov 2021→Oct 2023) |

## Peers (Diagnostics & Research)
IQV (IQVIA Holdings, Inc.) USD 278.32 +0.61% · WAT (Waters Corporation) USD 455.59 -0.41% · IDXX (IDEXX Laboratories, Inc.) USD 566.76 +2.40% · NTRA (Natera, Inc.) USD 401.37 -2.91% · ILMN (Illumina, Inc.) USD 269.4 -4.76% · MTD (Mettler-Toledo International, I) USD 1,684.64 +0.40%

## More
Full page: https://nexqual.com/A · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)


Other companies that name A in their own reports (relationship from A's side):

| Relationship | Company | Their filing | Sentence |
|---|---|---|---|
| customer | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | 10-K 2026-02-12 | "In 2020, we amended our commercial supply agreement with Agilent to provide for Agilent to supply, subject to any conflicting obligations under our third-party agreements, a specified percentage of th…" |

## Revenue by business segment (quarter ended 2026-07-31)

| Line | Revenue | Share | YoY | Operating income | Op. margin |
|---|---|---|---|---|---|
| Agilent CrossLab | $786.0M | 41.9% | +5.6% | $270.0M | 34.4% |
| Life Sciences and Diagnostics Markets | $746.0M | 39.7% | +11.3% | $176.0M | 23.6% |
| Applied Markets | $346.0M | 18.4% | +6.8% | $86.0M | 24.9% |
| Total revenue | $1.88B | 100% | — | $444.0M | 23.6% |

## Revenue by product line (quarter ended 2026-07-31)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Product | $1.33B | 71.0% | +8.4% |
| Non-Instrumentation and Other | $1.24B | 65.8% | +8.4% |
| Instrumentation | $643.0M | 34.2% | +7.3% |
| Services and Other | $545.0M | 29.0% | +7.3% |
| Total revenue | $1.88B | 100% | — |
The lines above cover 200% of total revenue.

## Revenue by region (quarter ended 2026-07-31)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Americas | $761.0M | 40.5% | +11.4% |
| Asia Pacific | $613.0M | 32.6% | +8.9% |
| Europe | $504.0M | 26.8% | +2.4% |
| Total revenue | $1.88B | 100% | — |

## Company outlook (8-K filed 2026-08-26)

- "Non-GAAP EPS (4) is expected in the range of $1.71 to $1.74 per share."
- "This guidance does not include any future benefit from tariff refunds."
- "All of this gives us confidence in our increased outlook and our ability to sustainably outperform our end markets." Financial Highlights Life Sciences and Diagnostics Markets Group The Life Sciences and Diagnostics Markets Group (LDG) reported third-quarter revenue of $746 million, growth of 11% reported and 10% core (1) year-over-year."
- "The forward-looking statements contained herein include, but are not limited to, information regarding Agilent's growth prospects, business, financial results, revenue, non-GAAP earnings guidance for fiscal year and fourth-quarter 2026, and the effects of its operational transformation and customer and market-focused strategy."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-10-31) | $1.73 | $1.72 | +0.7% | $1.99B | 17 |
| Next quarter (ends 2027-01-31) | $1.50 | $1.51 | -1.1% | $1.93B | 10 |
| Current fiscal year (ends 2026-10-31) | $6.20 | $6.06 | +2.4% | $7.50B | 20 |
| Next fiscal year (ends 2027-10-31) | $6.74 | $6.61 | +2.0% | $7.98B | 21 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-12-18 (includes earnings 2026-11-25): ±12.2%; earnings reaction alone ±4.3%; last 8 reports averaged ±4.9%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 28 | 36.5% | ±8.3% |
| 2026-12-18 | 56 | 38.7% | ±12.2% |
| 2027-01-15 | 84 | 35.3% | ±13.6% |
| 2027-02-19 | 119 | 35.8% | ±16.4% |
| 2027-03-19 | 147 | 35.9% | ±18.3% |
| 2027-05-21 | 210 | 35.7% | ±21.6% |
| 2027-06-17 | 237 | 36.3% | ±23.4% |
| 2027-09-17 | 329 | 36.2% | ±27.4% |